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HIGHLIGHTS1
2
 Many devices are coated with silver NPs and come in contact with oral 3
mucosa4
 19 nm AgNPs and only silver ions have been investigated through oral 5
porcine mucosa 6
 Results showed similar flux permeation in both experiments  7
 It can be suggested that the permeation is mainly due to ions released from 8
NPs 9
 AgNPs flux permeation through oral mucosa is higher compared to skin 10
permeation11
12
13
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Abstract 42
Silver nanoparticles (AgNPs) can come in contact with human oral mucosa due to 43
their wide use in food industry and hygiene devices. We evaluate transmucosal 44
absorption of 19 nm AgNPs using excised porcine buccal mucosa applied on Franz 45
diffusion cells. Two donor solutions were used: one containing AgNPs (0.5 g/L) and 46
one derived from the ultrafiltration of the former and containing only Ag in its 47
soluble form. Experiments were carried out separately for 4 hours. Silver flux 48
permeation was demonstrated through oral mucosa, showing similar values for 49
AgNPs (6.8 ± 4.5ng cm-2 h-1 ) and Ag ions (5.2 ± 4.3ng cm-2 h-1). Our study 50
demonstrates that silver can permeate the oromucosal barrier and that absorption 51
is substantially due to Ag ions, since no permeation difference was found using the 52
two solutions. Mucosal absorption has to be considered in further risk assessment 53
studies.54
55
Keywords: Silver nanoparticles, mucosal membrane, in vitro, Franz cells, 56
permeation.57
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1. Background: 70
71
Silver nanoparticles (AgNPs) are diffusely used in food packaging, containers, 72
toothpaste and teeth brushes, nipples and nursing bottles, water purification 73
devices etc. 1,2,3 These particles are therefore able to come in contact with oral 74
mucosa, whose penetration properties are not completely known. Silver is used for 75
its good antimicrobial properties and its safe profile,4 but in literature silver 76
intoxication (argyria) has been described through oral route, in people who drank it 77
for deliberate uptake, 5, 6 or through skin route, when wound dressings containing 78
Silver NPs are used on burns for more than 30% of the skin surface.7 The Agency 79
for Toxic Substances and Disease Registry (ATSDR) describes argyria as a “cosmetic 80
problem”, since it consist mostly in a not reversible bluish-gray discoloration of the 81
skin.8 Nevertheless there are isolated reports of more serious neurologic, renal and 82
hepatic complications caused by the ingestion of colloidal silver.9, 1083
Oral mucosa traditionally acts as first barrier to xenobiotics in the digestive tract, 84
but it is also a possible drug delivery route for medical formulations, 11 since it can 85
avoid liver metabolism if compared to the traditional intestinal route.12 86
Due to its histological structure oral mucosa shows a permeability 20 times higher 87
to water13 and 4 up to 4.000 times higher to different drugs compared to skin,14 but 88
very little is known about its behavior towards NPs penetration.  It has been 89
demonstrated that the main penetration barrier for drugs is the top third region of 90
the epithelium, because the cells size grows, and the cells shape becomes flatter 91
from the basal to the superficial layers. 1592
Since the spread of nanotechnologies has taken place in many fields of everyday 93
life, there are many available products containing AgNPs but the knowledge on NPs 94
permeation properties through mucosal membranes is still lacking.16 Some authors 95
demonstrated the capability of mucus layer to embed polystyrene NPs,17 others 96
demonstrated that them can cross this barrier and penetrate the buccal mucosa in 97
a size dependent manner.18 Nanosized pathogens too (Norwalk virus, 38 nm 98
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diameter, and HPV, 55 nm diameter) can easily diffuse through the mucus layer that 99
protect the gastric and nasal mucosa.18, 19 On this basis mucosal vaccines have 100
been developed in recent years and some of them are delivered through oral 101
mucosa (as the vaccines against cholera, rotavirus and typhoid fever) while others 102
through nasal mucosa by spray. 20, 21, 22 There is evidence that the administration of 103
antigens at mucosal portals of entry inside lipid nanocapsules can induce a T-104
cellular immune responses up to 13-fold higher rather than the equivalent soluble 105
formulation. 23106
Since NPs penetration through oral mucosa is not fully known, we performed  107
experiments to investigate AgNPs permeation. We chose to test AgNPs due to their 108
common use as antimicrobial agents in many devices that come in contact with oral 109
cavity. We used porcine lining mucosa because it is the most similar to the human 110
one13 and is the oral region which is expected to contribute most to oromucosal 111
absorption. In this study, experiments were performed using the Franz cell method, 112
adapting the experience and the protocols employed during the European project 113
EDETOX (Evaluations and predictions of DErmal absorption of TOXic chemicals)24, a 114
three-year research program (2001-2004) funded by European Union (EDETOX, 115
2000) and already used to testing skin permeation of other metal nanoparticles 116
such as silver, gold and cobalt.25, 26, 27117
118
119
2. Materials and methods1 0
121
2.1 Chemicals: 122
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All chemicals used were of analytical grade. Sodium chloride, sodium hydrogen 123
phosphate, potassium dihydrogen phosphate, glutaraldehyde (50% v/v), nitric acid 124
(69% v/v), hydrochloric acid (36.5-38% v/v) were purchased from Sigma Aldrich 125
(Milan, Italy), ammonium hydroxide (25%) from J.T. Baker (Milan Italy). Water 126
reagent grade was produced with a Millipore purification pack system (milliQ 127
water). 128
The physiological solution used as receptor fluid was prepared by dissolving 2.38 g 129
of Na2HP04, 0.19 g of KH2P04 and 9 g of NaCl into 1 L of milliQ water (final pH = 130
7.35)131
132
2.2 Silver nanoparticles characterization133
2.2.1 Donor phases preparation134
AgNPs, stabilized with polyvinylpirrolidone (content of silver: 25% w/w, polymer 135
75%), were supplied by NanoAmor Materials Inc, (Houston, Texas, U.S.A.). 136
In order to better distinguish the permeation between AgNPs and silver ions,137
released from the NPs, two different donor phases were prepared just before the138
experiments.139
The first donor phase, consisting of the AgNPs solution, was prepared using  200 140
mg (ratio metal:polymer=1:4) of AgNPs dispersed by sonication in 100 ml of 141
physiological solution to obtain a concentration of 0.50 g/L (as metal content). 142
The nanoparticles suspension in water had a presence of 5% of silver in ionized 143
form, determined using the ultrafiltration technique. The silver ions presence did 144
not significantly change in four hours.145
The second donor phase was prepared by the ultrafiltration of the first one to obtain 146
only the water-soluble silver species present in the first donor phase at the moment 147
of the experiment. Four ml of the AgNPs solution were ultrafiltered in centrifuge at 148
5000 rpm for 30 min by means of Amicon Ultra-4 centrifugal filters (10 KDa MWCO) 149
in order to separate the AgNPs from the aqueous solution. The filtration has been150
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repeated on five different aliquots in order to obtain an adequate solution volume to 151
perform silver quantification analysis and  permeation experiments. The five filtered 152
aliquots were mixed for a total of 20 ml and used during the permeation 153
experiments.154
2.2.2 Ion release from AgNPs155
In order to define the percentage of silver ions inside the AgNPs solution, the donor 156
phases have been analyzed by means of Inductively Coupled Plasma –Atomic 157
Emission Spectroscopy (ICP-AES).158
2.2.3 Transmission electron microscope characterization159
AgNPs dispersed in physiological solution were characterized to obtain nanoparticles 160
size and morphology on a transmission electron microscope (EM208; Philips, 161
Eindhoven, The Netherlands operating at 200 kV) with an high definition acquisition 162
system based on a side-mounted TEM camera OSIS Morada and a iTEM software 163
platform (Olympus Soft Imaging Solutions GmbH, Münster, Germany). 164
165
2.2.4 Dynamic light scattering measurements166
The average values of the AgNPs size and polydispersity, defined as a relative width 167
of the size distribution, were determined from dynamic light scattering (DLS) 168
measurements, using a Zetasizer Nano Z (Malvern Instruments Ltd) analyzer 169
applying a 633 nm laser oriented at 173° relative to the sample.170
The software was optimized to report summary statistics based upon the intensity 171
of light scattered. Four hundred µl sample volumes from nanosilver dispersion 172
(dilution 1:5 in physiological solution) were loaded into low size disposable cuvette 173
(supplied by manufacturer) and summary statistics were obtained using 174
quadruplicate 3 min analysis (total analysis time=12min). Instrument performance 175
was verified using a polymer reference standard known to be 60 nm.176
2.2.5 Zeta potential measurement177
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Measurements were carried out using a ZetasizerNano ZS (Malvern). An aqueous 178
suspension of silver nanoparticles was diluted 1:5 in a physiological solution. The 179
zeta potential was calculated using Henry’s equation.180
181
2.3 Preparation of mucosal membranes18
Due to its morphological and enzymatic similarities with the human mucosa13 183
porcine oral mucosa was used for the in vitro experiments. The membranes were 184
obtained immediately after pig’s slaughter (age 1 year). During the transport to 185
laboratory the tissue was stored at 4°C and then in freezer at -80°C for a period of 186
time up to, but not exceeding, 1 week. On the day of the experiment, the tissue 187
was removed from the freezer and thawed in physiological solution, at room 188
temperature, for approximately 30 min before the permeation experiment. It has 189
been shown that this method of storage does not affect the mucous barrier 190
properties, since no change in the permeability has been described.28The underlying 191
connective tissue was manually removed with a scalpel blade, and uniform 192
thickness of approximately 0,6 mm was achieved with surgical scissors. Mucous 193
membranes integrity was tested as suggested by Lestari. 29194
195
2.4 In vitro diffusion system196
Mucosal permeation studies were performed using static Franz diffusion cells. The 197
receiver compartments have a mean volume of 14.0 mL and were maintained at 198
37°C by means of circulation of thermostated water in the jacket surrounding the 199
cells throughout the experiment. This temperature value has been chosen in order 200
to reproduce physiological conditions. The concentration of the salt in the receiver 201
fluids was approximately the same that can be found in the blood. The solution in 202
each cell was continuously stirred using a Teflon coated magnetic stirrer. 203
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Each excised sheet of mucosa was clamped between the donor and the receptor 204
compartment in such a way that the epithelium faced the donor, and the connective 205
tissue region faced the receiver compartment; the mean exposed area of the 206
mucous membranes was 3.29 cm2.207
208
The experiments were performed as follows:209
Exp. 1: At time 0, the exposure chambers of 4 Franz diffusion cells were filled with 210
1 mL of physiological solution and 0.5 mL of AgNPs suspension (75 μg cm-2), in 211
order to provide an infinite dose: the concentration in each cell has been confirmed 212
at the end of the experiments by means of ICP-AES analysis. 213
At selected intervals (30, 60, 90, 120, 150, 180, 210, 240 min) 1 mL of the 214
receiving bathing solution was removed and collected for the analysis, and 215
immediately replaced with an equal volume of fresh made physiological solution. In 216
order to avoid the precipitation of silver chloride (AgCl), 100 µl of NH4OH 1N was 217
added to each sample collected. 218
The experiment was carried out for 4 hours, as suggested in other studies.16At the 219
end of the experiment the mucosa pieces were removed, washed abundantly with 220
milliQ water, and subsequently stored in the freezer together with mucosal bathing 221
solutions and the donor solutions for the following analysis222
The experiment was repeated twice for a total of 8 cells. 223
Exp. 2: the exposure chambers of 4 Franz diffusion cells were filled with 1 mL of 224
physiological solution and 0.5 mL of the Ag ultrafiltered solution. The other test 225
conditions were the same of the experiment 1. The experiment was repeated twice 226
for a total of 8 cells.227
Blanks: for each experiment, two cells were added as blank. The blank cells were 228
treated as the other cells with the exception that the exposure chambers were filled 229
only with physiological solution.230
Page 10 of 31
Ac
ce
pte
d M
an
us
cri
pt
10
2.5 Mucosa digestion after the experiment231
All the mucosal exposed samples were collected and stored individually in freezer at 232
-25° C for the following digestion and analysis. At the time of the analyzes, the skin 233
membranes were dried for 2 hours at room temperature, weight, and then cut into 234
sections and put into glass tubes with 10 mL of HNO3 69% v/v for digestion. The 235
obtained solutions were heated at 80°C for 8 hours and then diluted to a final 236
volume of 10 ml with milliQ water for the ICP-AES analysis.237
238
2.6 Quantitative analysis239
An Inductive Coupled Plasma Mass Spectrometer (ICP-MS 7500 CE Agilent 240
instrument with integrated autosampler) was used to determinate the total silver 241
concentration in the receiver phases.242
A seven-point standard curve was used for ICP-MS measurements (0.01, 0.05, 0.1, 243
0.5, 1, 5 and 10 µg/L, ion mass 107 u.m.a.). The limit of detection of silver was 244
0.005 μg/L for ICP-MS and the precision of the measurements expressed as 245
repeatability (RSD %) was always lower than 5%.246
The total silver concentration in the donor phases and in the solutions resulting 247
from the skin sample mineralization were performed by Inductively Coupled 248
Plasma-Atomic Emission Spectrometry (ICP-AES) using a Spectroflame Modula E 249
optical plasma interface (OPI) instrument (by SPECTRO, Germany). The analysis250
were conducted using a calibration curve obtained by dilution (range: 0–10 mg/L) 251
of Silver ICP standard solution for ICP-AES analysis (Sigma-Aldrich, Italy). The limit 252
of detection (LOD) at the operative wavelength of 328.068 was 0.010 mg/L. The 253
precision of the measurements expressed as repeatability (RSD %) was always 254
lower than 5%. 255
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All standard solutions used for calibration curves had been prepared using 256
physiological solution and 10% of ammonium hydroxide 1N in order to reproduce 257
the matrix of the samples.  258
259
2.7 SEM-EDX analysis260
One mucosal sample for each experiment (one blank, one exposed to AgNPs and 261
one to ultrafiltered soluble silver) was fixed with glutaraldehyde 10% v/v, washed 262
with ethanol-water at increasing concentration of ethanol and stored in ethanol 263
98% until SEM analysis.264
Analysis were performed by means of a Scanning Electron Microscope (Hitachi, TM 265
3000) equipped with Energy Dispersive X-ray Spectroscope (EDX SwiftEd 3000) 266
with a magnification of 30000x and an accelerating voltage of 15 kV. With this 267
setting silver clusters with a diameter above 50 nm were easily detected.268
269
2.8Data analysis270
Data analysis was performed with Excel for Windows, release 2007 and Stata 271
Software, version 11.0 (StataCorp LP, College Station, TX, USA). All data were 272
reported as mean or median as measures of central tendency and standard 273
deviation (SD) or quartiles as measure of dispersion. The difference among 274
independent data was assessed by means of the Mann-Whitney test. A p value of 275
<0.05 was considered as the limit of statistical significance.276
277
278
279
280
3. Results:281
3.1 characterization of AgNPs  colloidal dispersion 282
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The colloidal dispersion of AgNPs in water showed Plasmon absorption at 405 nm. 283
Transmission Electron Microscopy (TEM) measurements revealed that AgNPs used in 284
donor solution were quite uniform in size and shape and as small as 19 ± 5 nm 285
(number of measured nanoparticles: 100). At the concentration used in the 286
permeation experiments no aggregates have been visualized (fig. 1).287
The quantitative analysis of the filtered aliquots revealed that 5% of the donor 288
solution was ionized and a dose of 3.8 μg cm-2 of silver was applied as donor phase 289
in exp 2. Size distributions obtained by DLS are quite narrow, as presented in figure 290
2. The analysis revealed a z-average size (d.nm) equal to 57.1 and a polidispersity 291
index (PdI) of 0.28 (fig. 2), while Zeta potential was equal to – 11.4 ± 0.2 mV. 292
The apparent mismatch between TEM and DLS sizes is the result of various facts, 293
as elsewhere reported30. Firstly, the laser scattering technique measures the 294
hydrodynamic diameter inclusive of PVP and coordinated molecules. Furthermore, 295
polymer-protected metal NPs can form agglomerates consisting of various metal 296
cores wrapped up in the same polymer chain. The mean hydrodynamic diameters of 297
these agglomerates, revealed by DLS, are therefore larger than the mean sizes of 298
the primary NPs, revealed by TEM. 299
300
3.2 Ag permeation through mucous membrane301
Passive silver flux permeation was demonstrated through oral mucosa. Figure 3 302
shows the time-dependent increasing trend of metal concentrations in receiving303
phases. The final values, expressed as mean and standard deviation, were 12.2 ± 304
7.4 µg/cm² and 11.8 ± 11.1 µg/cm² in cells exposed to AgNPs and to Ag ions 305
(ultrafiltered solution), respectively. Flux permeation after 4 hours of application 306
showed similar final values (6.8 ± 4.5 ng cm-2 h-1 and 5.2 ± 4.3 ng cm-2 h-1) and 307
lag times (1.9 ± 0.7 h and 1.7 ± 0.7 h) using AgNPs and ultrafiltered solution, 308
respectively (mean and standard deviation).309
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Silver content inside the mucosa showed similar values in both experiments too 310
(median 0.8 µg/cm2 and 1.4 µg/cm2, 25th Pct 0.5 and 0.9, 75th Pct 0.1 and 0.2, in 311
membranes exposed to AgNPs and to Ag ions (ultrafiltered solution), respectively) 312
as showed in fig.4. 313
SEM-EDX investigations showed no traces of AgNPs clusters in the tissue. SEM 314
analysis revealed the presence of electrondense zones upon the mucosal tissue 315
exposed to Ag-NPs, but microanalysis on that points showed the absence of silver 316
or silver chloride particles (fig. 5A-F). 317
318
4. Discussion319
The oral mucosa is an attractive biological membrane, since it owns a dual role in 320
the body: on one side it acts as the first barrier towards xenobiotics and human 321
pathogens, and on the other it acts as the first gateway to systemic circulation 322
towards substances which can permeate it. Many drugs have been studied in order 323
to be absorbed through sublingual a ministration, but very few is known about 324
permeation properties towards nanoparticles. 325
Previous studies have shown that the oral mucosa permeability depends mainly on 326
the type of epithelium, the type and amount of intercellular lipids and the chemical 327
nature of the substances applied. Regions coated with nonkeratinized epithelium, 328
such as buccal mucosa and floor of mouth (lining mucosa), which we used in the 329
study, contain glycosylceramides, and have a significantly higher permeability 330
compared to regions with keratinized epithelium, such as hard palate and gengiva, 331
which contain predominantly neutral lipids. 31332
The first filter to external substances is the mucous layer 32 (average thickness of 333
70-100 µm), which consists mostly of a high molecular weight mucin, called MG1, 334
which is a component of the saliva that binds to the surface of the buccal 335
epithelium.33, 34 However it has been demonstrated that the main penetration 336
barrier for drugs is the top third region of the epithelium, due to the growing size 337
and shape of the cells that go up from the basal to the superficial layers.15338
The xenobiotics that can cross the hindrance of this barrier reach the underneath 339
connective tissue, called “lamina propria”,  which provides support and nourishment 340
to the mucosa through a network of blood vessels, capillaries and smooth341
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muscles,11 and from here substances can spread throughout the body via systemic 342
circulation. 343
AgNPs can come in contact with human mucosa because are present in many 344
products such as toothpaste, alcohol free mouthwash35, nasal sprays, endotracheal 345
tubes 36,37 and urinary catheters,38,39 to prevent infections. Since the antimicrobial 346
effect of silver depends on superficial contact, the high surface area to volume ratio 347
offered by NPs allows a broader interaction with bacterial membrane and a wider 348
contact with microorganisms.  349
Few studies have been conducted to investigate AgNPs behavior towards the 350
mucosa of the digestive tract. Shahare and colleagues 40 showed that after an oral 351
administration of 3-20 nm AgNPs to albino mice for 3 weeks, at a dose of 5, 10, 15 352
and 20 mg/kg body weight, all groups treated had a significant decrease in the 353
body weight, confirming a toxic effect of the metal. Histological changes of the 354
mucosa have been reported, such as a damage of the epithelial cell micovilli and 355
the intestinal glands, which the authors hypothesized as the reason for the 356
absorptive capacity reduction of intestinal epithelium and hence for the weight loss.  357
Walczak and colleagues41 investigated the behavior of 60 nm AgNPs and of AgNO3358
ions in an in vitro human digestion model. They found that after gastric digestion 359
and in presence of proteins, the number of particles dropped significantly, due to 360
the formation of clusters, and subsequently disintegrated back to single 60 nm 361
AgNPs during intestinal digestion. Therefore results showed that under physiological362
conditions AgNPs can reach the intestinal wall in their initial size.363
No other studies investigated AgNPs mucosal absorption but 2 studies 364
demonstrated that polystyrene Nps can cross the pig mucosa: Holpuch and 365
coworkers42 showed that 210 nm polystyrene NPs can cross intact human 366
epithelium, derived from oral explants, and can be found in the underlying 367
connective tissue. Teubl and colleagues18 investigated more systematically NPs 368
behavior through oral mucous membrane, by performing experiments with different 369
size and superficial charge of the NPs, and at different mucosal temperatures. They 370
demonstrated that neutral 25 nm, 50 nm and 200 nm polystyrene nanoparticles 371
(PP) can all cross the mucus layer and penetrate the buccal mucosa in a size 372
dependent manner, surprisingly higher for those with bigger size. This is in contrast 373
to the generally accepted assumption that decreasing the particle diameter374
increases the absorption43, 44.  375
Our study investigated for the first time the behavior of silver NPs and its 376
ultrafiltered solution towards oral mucosa, using 19 nm AgNPs applied in vitro on 377
porcine oral explants. The aim was to distinguish the percentage of permeation, if 378
any, due to NPs themselves from the percentage due to the ions issued. The 379
findings suggest that an absorption through passive diffusion takes place, and it is 380
mainly due to silver ions. This result is consistent with the ones obtained by other 381
authors, 45 whom demonstrated that the dose-dependent toxic effects of AgNPs on 382
animals (death, weight loss, cardiac enlargement, altered liver enzymes levels and 383
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immunological effects) were substantially mediated by silver ions released from 384
AgNPs. Gaillet and coworkers support the same theory in a recent review.46385
Indeed Silver, in whatever form, is not an essential mineral for humans, and so it 386
can exert toxic effects. Systemic intoxication, called “argyria”, is fortunately a rare 387
event, but a more common effect in human is the uptake reduction of some drugs, 388
such as thyroxine, penicillamine and of some antibiotics,47.389
For this reason the governmental agency Food and Drug Administration (FDA) 390
issued numerous warning letters to e-commerce sites which promoted colloidal 391
silver as antibiotic or drug for medical purposes.48, 49, 50392
It could be interesting compare our results with those obtained by Bianco and 393
coworkers,51 where AgNPs have been applied on full thickness human skin in similar 394
experimental conditions. Interestingly the flux through oral mucosa is about 1 order 395
of magnitude higher compared to skin, and the time required to reach a constant 396
flux trough the membrane is definitely lower through the mucosa. This higher 397
permeability is attributable to a slightly different histological structure of the 398
mucosa compared to skin.399
Our study adds important information to understand how nanoparticles can enter400
the body but nevertheless the protocol used presented some limitations related to: 401
1) the in-vitro condition, which can underestimate real world scenarios, since only 402
passive diffusion can be studied using Franz-cells and 2) the use of porcine mucosa, 403
which is a good model to study human’s mucosa but there are no data, yet, which 404
allow to bridge interspecies results. 405
406
407
5. Conclusions408
Our study investigated the permeation of 19 nm silver nanoparticles (AgNPs) across 409
excised porcine oral lining mucosa, using an in vitro diffusion cell system. 410
We demonstrated for the first time that AgNPs, can lead to silver absorption 411
through oral mucosa, in a similar amount when AgNPs or silver soluble form is 412
used, suggesting that the permeation of the mucosa is related mainly to ions413
diffusion. A further support to this hypothesis comes from the SEM-EDX results, 414
since no evidence of AgNPs clusters has been revealed, while the quantification of 415
total silver on the mineralized tissue ensures the presence of the metal.  416
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Moreover the comparison with flux permeation values through the skin barrier, 417
when similar experimental conditions were used, suggest that the permeability of 418
silver through oral mucosa is one order of magnitude greater compared to skin, 419
leading to a higher uptake in in-vivo conditions. 420
Even if the amount of silver found should be not hazardous for human health, these 421
data suggest that oral cavity should be part of further risk assessment studies, 422
since it acts as the first barrier for systemic uptake and can come in contact with 423
different types of nanoparticles. Moreover this study investigated only the intact 424
mucosa, but in everyday life there are common circumstances which may damage 425
the mucosal integrity, such as gastroesophageal reflux, infections or accidental 426
abrasions, which all can lead to an increase in the oromucosal uptake. 427
428
429
430
431
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FIGURE LEGENDS585
Fig.1. TEM images of the AgNPs dispersed in physiological solution: NPs appeared 586
uniform in size and shape and as small as 19 ± 5 nm (A: bar=200nm; B: 587
bar=100nm).588
589
Fig.2. DLS analysis.The curve represent AgNPs size distribution by intensity.The 590
summary statistics is based upon the intensity of light scattered of 6 different 591
samples derived from nanosilver dispersion. 592
593
Fig.3. Silver permeation profile in receiving phases of 8 cells exposed to AgNPs 594
(square) and of 6 cells ex osed to Ag ions (diamonds) expressed as mean and 595
standard deviation.596
597
Fig.4. Silver concentration in the mucosa of 7 cells exposed to AgNPs and 5 cells 598
exposed to Ag ions (median values, 25th and 75th quartiles, minimum and maximum 599
values, outsider value of 5.97 g/cm2 in the mucosa exposed to AgNPs not showed 600
in the figure). p = 0.61 (Mann-Whitney test).601
602
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Fig.5. SEM images at increasing magnifications of the mucosal tissue exposed to 603
AgNPs with EDX microanalysis on the yellow spots (A: the entire sample –604
bar=2mm; B: bar=500μm, C: bar=80μm, D: bar=70μm; E, F: bar=10μm).605
606
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Donor solution:  
 
1 mL of physiological solution and 0.5 
mL of AgNPs solution (75 μg cm-2) 
 
Donor solution : 
1 mL of physiological solution and 0.5 mL 
of the ultrafiltered  AgNPs solution  
(silver ions) 
 
1,5 ml samples 
 collected at selected intervals  
Filtered  
Separate experiments  
* 
Porcine oral 
mucosa 
Thermostated system 
 37°C 
Silver content inside oral mucosa after 4 h of  
exposure  
Silver content inside receiving solutions 
Results expressed as mean and standard deviation 
 
Median values, 25th and 75th quartiles, minimum and 
maximum values, p = 0.61 (Mann-Whitney test). 
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